Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12498676 | 0.91 | TACR1 (0.40) | TACR1POLBLMNASMN1; SMN2TP53 | |
| SCHEMBL12498474 | 0.85 | TACR1 (0.38) | TACR1POLBCRHR1TP53TDP1 | |
| SCHEMBL12499077 | 0.85 | TACR1 (0.38) | TACR1POLBCRHR1TP53TDP1 | |
| SCHEMBL12499604 | 0.84 | TACR1 (0.39) | TACR1POLBLMNASMN1; SMN2CRHR1 | |
| SCHEMBL12499632 | 0.83 | TACR1 (0.40) | TACR1POLBLMNASMN1; SMN2TP53 | |
| SCHEMBL12687173 | 0.80 | TACR1 (0.38) | TACR1POLBLMNASMN1; SMN2KDM4E | |
| SCHEMBL12499967 | 0.80 | TACR1 (0.41) | TACR1POLBLMNACRHR1KDM4E | |
| SCHEMBL12498745 | 0.79 | TACR1 (0.40) | TACR1CRHR1TDP1 | |
| SCHEMBL12499540 | 0.78 | TACR1 (0.40) | TACR1LMNASMN1; SMN2L3MBTL1CRHR1 | |
| SCHEMBL12499086 | 0.75 | CYP2C19 (0.40) | TACR1POLBLMNACRHR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029391-B2 | Isoquinoline compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-05-12 | — | — | US | disclosed |
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| WO-2012102985-A1 | ISOQUINOLINE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | MAVS, CCR5, NFATC1 | TACR1 4212/4885POLB 254/4885LMNA 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.